Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

AIMS : Loss-of-function mutations in ANGPTL3 are associated with beneficial effects on lipid and glucose metabolism and reduced risk of coronary artery disease. Vupanorsen (AKCEA-ANGPTL3-L Rx ) is an N-acetyl galactosamine-conjugated antisense oligonucleotide targeted to the liver that selectively i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaudet, Daniel, Karwatowska-Prokopczuk, Ewa, Baum, Seth J, Hurh, Eunju, Kingsbury, Joyce, Bartlett, Victoria J, Figueroa, Amparo L, Piscitelli, Philip, Singleton, Walter, Witztum, Joseph L, Geary, Richard S, Tsimikas, Sotirios, O'Dea, Louis St. L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Fast Track Congress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750927/
https://www.ncbi.nlm.nih.gov/pubmed/32860031
http://dx.doi.org/10.1093/eurheartj/ehaa689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750927/
https://www.ncbi.nlm.nih.gov/pubmed/32860031
http://dx.doi.org/10.1093/eurheartj/ehaa689

Ejemplares similares